Literature DB >> 19877742

Conclusions. Anidulafungin is a new echinocandin developed for more effective treatment of serious systemic fungal infections.

Pasquale De Bellis1.   

Abstract

Anidulafungin is a new echinocandin developed for more effective treatment of serious systemic fungal infections. Anidulafungin is a well tolerated echinocandin with a favorable pharmacokinetic profile; in particular, its lack of hepatic metabolism and renal excretion enables drug administration without dosage adjustment to subjects with any degree of impaired hepatic or renal function. This simplifies dosing, with a requirement for only once-daily administration and a lack of drug-drug interactions in patients who require multiple medications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19877742     DOI: 10.2165/11315580-000000000-00000

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  31 in total

Review 1.  Epidemiology, incidence and risk factors for invasive candidiasis in high-risk patients.

Authors:  Ercole Concia; Anna Maria Azzini; Michela Conti
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 2.  Clinical aspects of invasive candidiasis in critically ill patients.

Authors:  Mariano Pennisi; Massimo Antonelli
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 3.  The safety of anidulafungin.

Authors:  José A Vazquez
Journal:  Expert Opin Drug Saf       Date:  2006-11       Impact factor: 4.250

Review 4.  An overview of fungal infections.

Authors:  G Garber
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Nosocomial bloodstream infections in United States hospitals: a three-year analysis.

Authors:  M B Edmond; S E Wallace; D K McClish; M A Pfaller; R N Jones; R P Wenzel
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

6.  Early clinical experience with anidulafungin at a large tertiary care medical center.

Authors:  Benjamin D Brielmaier; Ed Casabar; Christine M Kurtzeborn; Peggy S McKinnon; David J Ritchie
Journal:  Pharmacotherapy       Date:  2008-01       Impact factor: 4.705

7.  Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal.

Authors:  James A Dowell; William Knebel; Tom Ludden; Marty Stogniew; David Krause; Tim Henkel
Journal:  J Clin Pharmacol       Date:  2004-06       Impact factor: 3.126

Review 8.  Clinical aspects of invasive candidiasis in paediatric patients.

Authors:  Elio Castagnola; Silvia Buratti
Journal:  Drugs       Date:  2009       Impact factor: 9.546

9.  In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

10.  Anidulafungin versus fluconazole for invasive candidiasis.

Authors:  Annette C Reboli; Coleman Rotstein; Peter G Pappas; Stanley W Chapman; Daniel H Kett; Deepali Kumar; Robert Betts; Michele Wible; Beth P Goldstein; Jennifer Schranz; David S Krause; Thomas J Walsh
Journal:  N Engl J Med       Date:  2007-06-14       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.